Last updated: July 23, 2026
SUPERNUS PHARMACEUTICALS v. ZYDUS PHARMACEUTICALS (USA), INC. 2:14-cv-07272: Litigation Summary, Claims In Scope, and Case Posture
Executive summary: SUPERNUS PHARMACEUTICALS, INC. v. ZYDUS PHARMACEUTICALS (USA) INC., case no. 2:14-cv-07272, is a patent-infringement dispute tied to FDA Hatch-Waxman/Orange Book-type generics timing. The available record in this chat does not include the asserted patents, complaint counts, claim construction outcomes, scheduling milestones, final judgment, or settlement terms. Without those particulars, a complete and accurate litigation “summary and analysis” cannot be produced.
What patents did SUPERNUS assert vs ZYDUS in 2:14-cv-07272?
Featured snippet answer: The specific patents asserted (numbers), remaining claim(s) at issue, and the asserted product/NDA are not provided in the input, so the asserted patent scope cannot be identified here.
Which infringement theories were pleaded (direct, induced, contributory)
The pleadings details (theory of infringement, product mapping to claims, and alleged acts in the US) are not present in the input.
What claims of the asserted patents survived to later stages
Claim selection and any later narrowing are not provided.
What did ZYDUS challenge in its Paragraph IV ANDA filing for the case?
Featured snippet answer: The record here does not identify the ANDA reference listed drug (RLD), generic applicant, ANDA number, or whether the challenge was Paragraph IV or another statutory mechanism.
What FDA pathway is implicated
The input does not specify whether the case relates to an ANDA approval, tentative approval, or a settlement tied to launch timing.
What ZYDUS argued on invalidity and non-infringement
Invalidity grounds (35 USC 102/103/112), inequitable conduct, or non-infringement contentions are not included.
How did the court handle motions in SUPERNUS v. ZYDUS, 2:14-cv-07272?
Featured snippet answer: No procedural history is included in the input for motion practice, including:
- dismissal/pleading sufficiency motions,
- summary judgment motions,
- Daubert/experts,
- claim construction (Markman) outcomes,
- stays pending PTO reexamination or IPR.
Were any claims stayed pending PTO proceedings?
No information is provided.
Were there interim rulings on claim construction or expert admissibility
No information is provided.
When did the SUPERNUS v. ZYDUS case reach judgment, dismissal, or settlement?
Featured snippet answer: Final disposition dates and outcome (judgment vs dismissal vs settlement) are not provided in the input.
Did the parties settle with a license or pay-for-delay style agreement?
No settlement terms are provided.
What launch/timing terms were agreed (if any)
No FDA exclusivity, stipulated design-around, or launch dates are provided.
What is the case’s current posture for enforcement and generic entry risk?
Featured snippet answer: The current posture cannot be determined from the input because there is no data on:
- whether any injunction issued,
- whether appeals are pending,
- whether the patents were held invalid,
- whether the case was closed by settlement.
What enforcement rights survived (if any)
No information is included.
How the ruling affects ZYDUS’s ability to launch
No launch conclusion is provided.
How strong was SUPERNUS’s patent estate in this litigation (infringement/validity outcomes)?
Featured snippet answer: The litigation outcome and claim-level results are not provided, so strength-by-result cannot be assessed.
Were the asserted patents upheld or narrowed
No rulings are provided.
What prior art and secondary considerations were used
No invalidity record is provided.
How does this case compare with other SUPERNUS patent fights involving Hatch-Waxman generics?
Featured snippet answer: A comparative analysis requires case-specific outcomes (asserted patents, RLD, trial results, settlement posture) for this matter and adjacent matters, none of which are included.
Commonality in asserted chemistry/formulation vs method-of-use
No details are provided.
Key takeaways
- 2:14-cv-07272 is identified, but the asserted patent numbers, NDA/ANDA linkage, procedural milestones, and final disposition are not present in the input.
- Without those facts, any “litigation summary and analysis” would be incomplete.
FAQs
- What RLD and ANDA are linked to SUPERNUS v. ZYDUS 2:14-cv-07272?
- Which asserted patents (numbers and expiration dates) were in dispute?
- Did the court conduct a Markman hearing, and what were the claim construction holdings?
- Was there a settlement, and what were the post-settlement launch or design-around terms?
- Is any appeal or ongoing enforcement associated with 2:14-cv-07272?
References (APA)
- Not provided in the input.
